Pinetree Therapeutics, Inc. Secures $23.5 Million Of Series A1 Funding To Develop Cutting Edge Platform Technology To Create Therapeutic Assets For Unmet Medical Needs
Pinetree Therapeutics, Inc. Secures $23.5 Million Of Series A1 Funding To Develop Cutting Edge Platform Technology To Create Therapeutic Assets For Unmet Medical Needs
06/07/22, 10:00 AM
Money raised
$23.5 million
Round Type
series a
PineTree Therapeutics, Inc., an emerging leader in pioneering the development of disruptive therapies in Oncology, Immuno-oncology and other diseases, announced that the company has raised $23.5 Million for Series A1 funding. The investments, which will be used to advance our Oncology and Viral Diseases platforms, were made by InterVest, SK Securities, DSC Investment, J Curve Investment, Samho Green Investment, and SJ Investment Partners.
Company Info
Additional Info
PineTree Therapeutics, Inc., an emerging leader in pioneering the development of disruptive therapies in Oncology, Immuno-oncology and other diseases, announced that the company has raised $23.5 Million for Series A1 funding. According to HoJuhn Song, Co-Founder and CEO of PineTree Therapeutics, the company has developed a highly differentiated platform to solve the world's difficult-to-treat diseases, which require unconventional approaches to deliver a new paradigm on providing real and meaningful benefits for patients. The firm gained its early reputation from successful invests into Biotech ventures such as ABL bio. About PineTree Therapeutics, Inc.PineTree Therapeutics is a pre-clinical stage Biotech company headquartered in Cambridge, MA and was founded in 2019.